Abstract
Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan (Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with previously untreated pancreatic cancer were given irinotecan and gemcitabine were promising, with two of three patients achieving a partial response. Because of the favorable outcome of the phase I study, a multicenter phase II trial was undertaken in previously untreated patients with pancreatic carcinoma. Data from other sites entering patients in this phase II study have been analyzed, and a multicenter phase III trial of single-agent gemcitabine vs the irinotecan combination in first-line treatment of patients with locally advanced or metastatic pancreatic cancer is underway.
Original language | English (US) |
---|---|
Pages (from-to) | 31-33 |
Number of pages | 3 |
Journal | ONCOLOGY |
Volume | 14 |
Issue number | 12 SUPPL. 14 |
State | Published - Dec 1 2000 |
ASJC Scopus subject areas
- Oncology
- Cancer Research